Sulzer orders down:
This article was originally published in Clinica
Executive Summary
Sulzer Medica saw sales rise by 15% or 4% adjusted for acquisitions and currency translation, to SwFr1,183 million ($788 million). The Swiss company says that the current weakness in the US$ is unlikely to affect the 1998 results significantly. The parent company, Sulzer Technology, says that its orders dropped in the first nine months by 6%, or 4% when adjusted for currency fluctuations, to SwFr4,376 million.